O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus
Bibliographic record
Abstract
Objective Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to severe plaque psoriasis. Deucravacitinib inhibits TYK2-mediated signaling of cytokines, such as type 1 interferons, involved in systemic lupus erythematosus (SLE). In the 48-week, double-blind, phase 2 PAISLEY trial in patients with active SLE (NCT03252587), all primary and secondary endpoints were met at the 3 mg twice-daily (BID) deucravacitinib dose, including SLE Responder Index-4 (SRI[4]) response rates vs placebo at weeks 32 (primary endpoint) and 48. Week 32 response rates were 34.4% vs 58.2%, 49.5%, and 44.9% with placebo vs deucravacitinib 3 mg BID, 6 mg BID, and 12 mg once daily (QD), respectively. This exploratory analysis assessed the efficacy of deucravacitinib according to patient baseline characteristics. Methods In the PAISLEY trial, patients with active SLE were randomized 1:1:1:1 to receive placebo (n=90) or deucravacitinib 3 mg BID (n=91), 6 mg BID (n=93), or 12 mg QD (n=89). SRI(4) response rates at week 32 in the phase 2 PAISLEY trial were evaluated according to select baseline demographics and disease characteristics. Point estimates for response rates with asymptotic CIs were calculated for each treatment arm within each subgroup. All analyses were descriptive. Results SRI(4) response rates in most analyzed subgroups were consistent with the observed response rates in the overall population and favored the 3 mg BID deucravacitinib dose. SRI(4) response rates in subgroups defined by race, baseline SLEDAI-2K and glucocorticoid dose, and years since initial diagnosis are provided below (figure 1). Of these, Black/African American race, other race, baseline SLEDAI-2K of <10, baseline glucocorticoid dose of ≥10 mg/day, and 3–6 and ≥6 years since diagnosis showed the greatest difference in SRI(4) responses for those receiving deucravacitinib vs placebo. Conclusion Deucravacitinib was associated with improved SRI(4) response rates at week 32 across race, SLEDAI-2K, glucocorticoid dose, and years since diagnosis at baseline subgroups. Data interpretation for some subgroups was limited by low patient numbers. These findings support the efficacy of deucravacitinib in the treatment of patients with active SLE, regardless of patient baseline characteristics. Acknowledgements We thank the patients and their families who made this study possible, as well as the clinical teams who participated. This study was sponsored by Bristol Myers Squibb. Professional medical writing assistance was provided by Angela R. Eder, PhD, of SciMentum, Inc, a Nucleus Group Holdings, Inc, company, and funded by Bristol Myers Squibb. COI Disclosures EM: Research support: AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, GSK, Janssen, and UCB; Consultancy: AstraZeneca, Biogen, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, Novartis, and Servier CA: Grant support: AstraZeneca and Bristol Myers Squibb; Advisor or review panel: AstraZeneca, Aurinia, Bristol Myers Squibb, GSK, and Kezar; Speaker/honoraria: AstraZeneca and Aurinia LGP: Consultancy: Aurinia and Bristol Myers Squibb AC: Research support: AstraZeneca and GSK; Consultancy/Speaker: AstraZeneca and GSK; Consultancy: Bristol Myers Squibb, Otsuka, and Roche SP, CH, TW, and SB: Employees and shareholders: Bristol Myers Squibb RK: Employee of Syneos Health, providing statistical services to Bristol Myers Squibb RvV: Research support: Bristol Myers Squibb, GSK, and Eli Lilly; Research support, consultancy, and speaker: UCB; Support for educational programs, consultancy, and speaker: Pfizer; Support for educational programs: Roche; Consultancy and speaker: AbbVie, Galapagos, and Janssen; Consultancy: AstraZeneca, Biogen, Biotest, Celgene, Gilead, and Servier
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.003 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.008 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".